SWOG 2408: Lanreotide vs Placebo Before Surgery to Prevent Pancreatic Fistula

SWOG 2408: A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

IDENTIFIER (ClinicalTrials.gov): NCT06807437

DRUG/TREATMENT: Lanreotide

PHASE: 3

STATUS: Recruiting

SPONSOR: SWOG Cancer Research Network

DESCRIPTION:

This is a Phase III clinical trial studying whether a medication called lanreotide can help reduce the risk of a common surgical complication in people undergoing pancreas surgery (distal pancreatectomy) for pancreatic cancer or pre-cancerous lesions.

What is Lanreotide?

Lanreotide is a type of medication called a somatostatin analog, which is similar to a natural hormone in the body. It is already used to treat some neuroendocrine tumors (NETs) and can help control hormone levels and tumor growth.

In this study, researchers are looking at whether giving lanreotide before surgery can help prevent complications.

About the Study

After pancreas surgery, some patients develop a complication called a pancreatic fistula, which is a leak of fluid from the pancreas that can lead to infection and other problems.

This study is designed to find out:

• Whether lanreotide before surgery can reduce the risk of pancreatic fistulas

• Whether it can improve recovery, hospital stay, and quality of life

How the Study Works

Participants are randomly assigned (like flipping a coin) to one of two groups:

• Lanreotide group: receives a single injection before surgery

• Placebo group: receives a look-alike injection with no active drug

  
  

Neither patients nor doctors will know which group they are in (a blinded study) to ensure fair and accurate results.

Who Can Join

This study is for adults who:

• Have pancreatic cancer or a pancreatic lesion

• Are planning to undergo distal pancreatectomy (surgical removal of part of the pancreas)

What Participation Involves

• A single injection before surgery

• Standard pancreas surgery

• Monitoring for complications and recovery

• Follow-up visits and questionnaires about recovery and quality of life

• 
  

Why This Matters

Pancreatic fistulas are a common and serious complication after pancreas surgery. If lanreotide can help reduce this risk, it could improve recovery and outcomes for patients undergoing these procedures.

CONTACT

For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.

This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov  for site-specific contact information.